Carnosinase-1 overexpression, but not aerobic exercise training, affects the development of diabetic nephropathy in BTBR ob/ob mice by Everaert, Inge et al.
RESEARCH ARTICLE
Carnosinase-1 overexpression, but not aerobic exercise training, affects the
development of diabetic nephropathy in BTBR ob/ob mice
Inge Everaert,1* Junling He,2* Maxime Hanssens,1* X Jan Stautemas,1 Kim Bakker,2 Thomas Albrecht,3
Shiqi Zhang,3 Thibaux Van der Stede,1 Kenneth Vanhove,1 David Hoetker,4 Michael Howsam,5
Frédéric J. Tessier,5 Benito Yard,3 Shahid P. Baba,4 Hans J. Baelde,2 and Wim Derave1
1Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium; 2Department of Pathology, Leiden
University Medical Center, Leiden, The Netherlands; 3Fifth Medical Department, Universitätsklinikum Mannheim, Mannheim,
Germany; 4Diabetes and Obesity Center, University of Louisville, Louisville, Kentucky; and 5Inserm, CHU Lille, Pasteur
Institute of Lille, University of Lille, Lille, France
Submitted 17 July 2019; accepted in final form 28 February 2020
Everaert I, He J, Hanssens M, Stautemas J, Bakker K, Al-
brecht T, Zhang S, Van der Stede T, Vanhove K, Hoetker D,
Howsam M, Tessier FJ, Yard B, Baba SP, Baelde HJ, Derave W.
Carnosinase-1 overexpression, but not aerobic exercise training, af-
fects the development of diabetic nephropathy in BTBR ob/ob mice.
Am J Physiol Renal Physiol 318: F1030–F1040, 2020. First published
March 9, 2020; doi:10.1152/ajprenal.00329.2019.—Manipulation of
circulating histidine-containing dipeptides (HCD) has been shown to
affect the development of diabetes and early-stage diabetic nephrop-
athy (DN). The aim of the present study was to investigate whether
such interventions, which potentially alter levels of circulating HCD,
also affect the development of advanced-stage DN. Two interven-
tions, aerobic exercise training and overexpression of the human
carnosinase-1 (hCN1) enzyme, were tested. BTBR ob/ob mice were
either subjected to aerobic exercise training (20 wk) or genetically
manipulated to overexpress hCN1, and different diabetes- and DN-
related markers were compared with control ob/ob and healthy (wild-
type) mice. An acute exercise study was performed to elucidate the
effect of obesity, acute running, and hCN1 overexpression on plasma
HCD levels. Chronic aerobic exercise training did not affect the
development of diabetes or DN, but hCN1 overexpression accelerated
hyperlipidemia and aggravated the development of albuminuria, mes-
angial matrix expansion, and glomerular hypertrophy of ob/ob mice.
In line, plasma, kidney, and muscle HCD were markedly lower in
ob/ob versus wild-type mice, and plasma and kidney HCD in partic-
ular were lower in ob/ob hCN1 versus ob/ob mice but were unaffected
by aerobic exercise. In conclusion, advanced glomerular damage is
accelerated in mice overexpressing the hCN1 enzyme but not pro-
tected by chronic exercise training. Interestingly, we showed, for the
first time, that the development of DN is closely linked to renal HCD
availability. Further research will have to elucidate whether the
stimulation of renal HCD levels can be a therapeutic strategy to
reduce the risk for developing DN.
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INTRODUCTION
Twenty to forty percent of patients with type 2 diabetes
develop diabetic nephropathy (DN). As no optimal treatment
for DN is currently available, this frequently results in end-
stage renal disease and dependence on dialysis. A growing
body of evidence suggests a protective role of carnosine
against DN. Carnosine and its methylated analog anserine are
histidine-containing dipeptides (HCD), consisting of amino
acids -alanine and histidine and -methylhistidine, respec-
tively, which are available in the diet of omnivorous subjects.
They possess some beneficial biochemical properties, such as
antioxidative, metal chelating, and antiglycation properties,
which enable them to attenuate the development of DN (for a
review, see Ref. 6).
Genetic studies have revealed an association of a polymor-
phism in the carnosinase-1 gene (CNDP1), the enzyme respon-
sible for the hydrolysis of carnosine in the circulation, and the
prevalence of DN, especially in female patients with type 2
diabetes (13, 21, 29). Although carnosine is only present in the
low nanomolar range in the fasted state (because of the very
active carnosinase-1 enzyme) (41), it has been hypothesized
that a higher circulating carnosine content upon dietary intake
was the underlying mechanism for protection against DN
(12, 42).
Long-term supplementation of carnosine in drinking water
has repeatedly been shown to protect against early signs of DN
in different diabetic rodent models [db/db mice (35), obese
Zucker rats (2), and streptozotocin-induced diabetic rats (34,
52)] and recently also in BTBR ob/ob mice, which have DN
with severe glomerular lesions (1). Reducing the amount of
circulating carnosine levels, on the other hand, has been
achieved by overexpressing the human carnosinase-1 (hCN1)
enzyme, which is only present in humans and not in rodents.
This resulted in a more pronounced diabetic state (as reflected
by hyperglycemia, HbA1c, and insulin) in db/db mice (42).
However, since db/db mice are slow to develop advanced DN,
the effect of reduced circulating carnosine levels on DN in a
model with more pronounced DN (BTBR ob/ob) was investi-
gated in the present study.
HCD are mainly present in skeletal muscle but also in lower
amounts in kidney tissue. Owing to its high concentration in
skeletal muscles and their total volume, it is estimated that
~99% of the carnosine body burden is stored in skeletal
muscle. Therefore, a potential alternative way to manipulate
circulating carnosine levels is hypothesized to be the release of
carnosine from skeletal muscle as a result of physical exercise.
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Both mice and horses were characterized by higher carnosine
content in their circulation when being physically active (11,
30). Human evidence is scarce, but muscle interstitium carnos-
ine levels were increased in response to submaximal leg
exercise (32).
Interestingly, it has been established that prolonged aerobic
exercise training could protect different diabetic rodent models
against the increase in urinary albumin and other pathophysi-
ological characteristics of DN (39, 49, 51). Intervention studies
investigating the effects of exercise training on the develop-
ment of DN in patients with diabetes are lacking (10); how-
ever, one prospective study revealed that moderate- and high-
intensity leisure-time physical activity attenuate the initiation
and progression of DN (50). We thus hypothesized that part of
the protective effect of exercise training on DN is mediated by
enhanced circulating carnosine and/or anserine, which are
released from muscular storage sites upon muscle contractile
activity. This could be a novel therapeutic insight on the
benefits of exercise, in addition to the more commonly pro-
posed mechanism that exercise training can improve glycemic
control (43).
The aim of the present study was to investigate whether
overexpression of the hCN1 enzyme or chronic aerobic exer-
cise training, interventions potentially resulting in decreased
and increased circulating HCD levels, respectively, could af-
fect the development of DN in mice that develop glomerular
lesions that closely resemble an advanced stage of human DN
[BTBR ob/ob mice (19)]. An acute study was performed to
evaluate the effect of obesity, acute exercise, and hCN1 over-
expression on plasma and muscle HCD levels. A chronic study
further examined the development of diabetes and DN in ob/ob
mice compared with that in 1) ob/ob mice that underwent a
treadmill-based aerobic exercise training protocol for 20 wk
and 2) ob/ob mice that were genetically manipulated to over-
express the hCN1 enzyme.
METHODS
The experimental protocol was approved by the Ethics Committee
for Animal Research at Ghent University and followed the Principles
of Laboratory Animal Care.
Generation and Genotyping of Experimental Mice
Human carnosine dipeptidase 1 (hCNDP1) transgenic mice were
generated in the BTBR wt/ob (Black and Tan, BRachyuric) back-
ground as previously described in db/db mice (42). Briefly, the cDNA
of hCNDP1 including the endogenous signal peptide of six leucines
was amplified from IMAGE clone Accession No. BX094414 with the
primers 5=-PCACCATGGATCCCAAACTCGGGA-3= (CNDP1 for-
ward) and 5=-PTCAATGGAGCTGGGCCATCT-3= (CNDP1 re-
verse). PCR products were ligated behind the transthyretin promoter
into the StuI site of plasmid pTTR1ExV3. Thereafter, DH5-compe-
tent Escherichia coli were transformed with hCNDP1 containing
pTTR1ExV3. Transformed E. coli were propagated with standard
protocols. For isolation of the hCNDP1-pTTR1ExV3 plasmid, a
Maxi-Prep plasmid purification kit (Qiagen, Hilden, Germany) was
used. Thereafter, the fragment containing hCNDP1 and the TTR1
promoter was cut from the plasmid by HindIII digestion. The
purified fragment was injected into the pronuclei of the fertilized
ovum of a BTBR ob/wt female mouse (stock no. 004824, Jackson
Laboratories, Bar Harbor, ME). All animal procedures were ap-
proved by the Regierungspräsidium Karlsruhe (AZ 35-9185.81/G-
116/14 and G-108/13). The fertilized ovum was transplanted into
the oviduct of a pseudopregnant mouse that had been induced to
act as a recipient by mating with a vasectomized male mouse. In
separate experiments from our research group, we previously
observed that hCN1 overexpression in ob/wt mice did not result in
metabolic disturbances, reflected by similar levels of HbA1c and
the albumin-to-creatinine ratio in transgenic versus nontransgenic
ob/wt mice (B. Yard et al., unpublished data).
hCN1 transgenic BTBR mice were crossbred with BTBR ob/wt mice
(line 004824, The Jackson Laboratory). The Lepob point mutation and
overexpression with hCN1 was checked by quantitative PCR (high-
resolution melting analysis, based on Ref. 47). DNA was isolated from
tails of 7- to 11-day-old pups with the Invisorb Spin tissue mini kit
(Stratec Molecular). DNA content was quantified with NanoDrop
(ThermoFisher Scientific) and diluted with elution buffer to a final
concentration of 25 ng/L. For the ob point mutation, primer mix (0.4
L, final concentration: 2 M, forward: 5=-CAGATAGCCAATGAC-
CTGGAG-3= and reverse: 5=-TCTTGGAGAAGGCCAGCAGAT-3=),
JumpStart Taq ReadyMix (6 L, Sigma-Aldrich), SYBR Green PCR
Master Mix (1.2 L, Life Technologies), and DNA (0.5 L) were added
to a LightCycler 480 multiwell plate. For the CN1 transgene, primer mix
(0.4 L, final concentration: 2 M, forward 5=-CCTCGCTTCAGA-
CAAGAGCTCTTCAGAATGA-3= and reverse 5=-GCTCTGAAGG-
CGCTCACAGCATTGATCCAA-3=), JumpStart Taq ReadyMix (3.6
L, Sigma-Aldrich), SYBR Green PCR Master Mix (3.6 L, Life
Technologies), and DNA (0.5 L) were used. Amplification and melt
curve analysis was performed on a Roche LightCycler 480 instrument
using the following parameters: detection format: SYBR green I, prein-
cubation (95°C for 3 min), amplification/quantification (95°C for 30 s,
58°C for 30 s, and 72°C for 1 min with single acquisition; 38 cycles),
high-resolution melting (95°C for 1 min, 40°C for 1 min, 65°C for 1 s,
and 90°C with 25 acquisitions per °C). The genotyping was validated by
evaluating the phenotypes, i.e., obesity and plasma CN1 activity, respec-
tively.
Experimental Design
Acute study. Four- to six-week-old wild-type (WT; n  17), ob/ob
(n  29), and ob/ob hCN1 (n  5) mice were included in these
experiments (Table 1). After five familiarization sessions (in 2 wk),
mice were placed on either a running treadmill (ob/ob EX; 10 m/min,
n  14) or a stationary treadmill (ob/ob; n  14) for 1 h. Mice were
immediately sedated (80% Ketalar-20% Rompun) after 1 h, blood was
collected as quickly as possible in precooled EDTA tubes and centri-
fuged at 14,000 g for 5 min, and collected plasma was stored, after
deproteinization with sulfosalicylic acid (SSA), at 20°C. Gastroc-
Table 1. Acute study: basic group characteristics
Number of Mice
(Male/Female) Age, wk Body Weight, g Carnosinase-1 Activity, mol·mL1·h1
WT 17 (8/9) 8.3  0.7 28.1  3.0 	LOD
ob/ob 15 (6/9) 7.5  1.5 47.3  6.5 	LOD
ob/ob EX 14 (7/7) 7.0  1.3 47.7  8.3 	LOD
ob/ob hCN1 5 (2/3) 6.6  1.1 44.2  8.7 6.04  0.94
Values are means  SD for the numbers of mice indicated. The following groups are shown: wild type (WT) mice, ob/ob mice, ob/ob mice with acute exercise
(EX), and ob/ob human carnosinase-1 transgenic (hCN1) mice. LOD, limit of detection.
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nemius muscle was immediately collected after cervical dislocation,
snap frozen in liquid nitrogen, and stored at 80°C.
Chronic study. Four-week-old BTBR mice were randomly allo-
cated to the following four experimental groups: WT (n  15), ob/ob
(n  19), ob/ob with exercise training (EX-T; n  19), and ob/ob
hCN1 (n  16) (Table 2). Male and female mice were included
equally. Exercise training, on a Columbus Exer-3/6 open treadmill,
was initiated at the age of 4 wk with a familiarization period of 2 wk,
in which running time and intensity were gradually increased up to 10
m/min for 1 h. Mice were closely monitored during running and were
removed from the treadmill when they refused (e.g., because of
injury) to leave the electrical grid. At the age of 4 and 24 wk, daily
food and water intake (mean value per cage, mice having been placed
in separate cages per group, sex, and age) and body weight were
monitored. At weeks 4, 14, and 24, fasted (4–6 h) serum was collected
via the tail vein and diluted with 0.9% NaCl for further analysis.
Fasted (4–6 h) spot urine was collected at weeks 4, 8, 12, 14, and 24.
Euthanasia took place at the age of 24 wk. One kidney was removed
(snap frozen and stored at 80°C) under isoflurane anesthesia, after
which whole body perfusion (heart left ventricle) with saline was
performed. The remaining, perfused kidney was placed in formalin
solution (neutral buffered, 10%, Sigma-Aldrich) for 24 h, after which
it was stored in 70% ethanol at room temperature embedded in
paraffin. The perfused gastrocnemius was further dissected and stored
at 80°C until analysis. Fasted serum glucose, triglycerides, and
cholesterol were measured in the Clinical Laboratory of University
Hospital UZ Ghent with a Roche/Hitachi Cobas C according to the
manufacturer’s procedures. Serum protein levels were evaluated by
means of the Total Protein Kit Micro-Lowry, Onishi & Barr Modifi-
cation (catalog no. TP0200, Sigma).
Histological Analysis
Paraffin-embedded kidney tissue was cut on a Leica microtome
(Wetzlar). Sections (4-m thickness) were deparaffinized and rehy-
drated according to a standard protocol. Sections were stained with
periodic acid-Schiff as well as hematoxylin and eosin. Stained slides
were digitalized with the Philips Ultra Fast Scanner 1.6 RA (Philips
Electronics) for morphological measurement. The surface areas (m2)
of the whole glomerulus, Bowman’s space, and glomerular tuft of 25
randomly chosen glomeruli were measured with ImageJ software to
examine glomerular hypertrophy. Periodic acid-Schiff-stained kidney
tissue was graded in a blinded manner by two independent observers
on a scale of 03, depending on the amount of the mesangial matrix
(0: 0–25%, 1: 25–50%, 2: 50–75%, and 3: 
75%), in 25 randomly
chosen glomeruli. Interstitial fibrosis was determined by sirius red
staining.
Immunohistochemistry
Sections were deparaffinized, rehydrated, and thereafter stained for
Wilms’ tumor-1 protein. Antigen retrieval was performed with Tris-
EDTA buffer. Sections were incubated with rabbit anti-Wilms’ tu-
mor-1 (1:1,000, Santa Cruz Biotechnology, Santa Cruz, CA) followed
by an anti-rabbit-Envision, horseradish peroxidase-labeled secondary
antibody (Dako). As a negative control, normal rabbit serum was used
as the primary antibody. Immunostaining was visualized with di-
aminobenzidine (DAB, Dako) as the chromogen. Thereafter, sec-
tions were counterstained with hematoxylin and eosin, dehydrated,
and mounted. Sections were imaged with a Philips Ultra-Fast Scanner
1.6 RA (Philips Electronics). The number of podocytes in each sample
was determined by counting the number of Wilms’ tumor-1-positive
nuclei per glomerulus in 25 randomly chosen glomeruli.
Urinary Albumin
Urine albumin levels were measured with rocket immunoelectro-
phoresis against rabbit anti-mouse albumin, and purified mouse serum
albumin (Sigma-Aldrich) was used as the standard. Urine creatinine
levels were measured with a creatinine assay with picric acid, sodium
hydroxide, and creatinine standards (Sigma-Aldrich). Thereafter, the
albumin-to-creatinine ratio was calculated. The rabbit anti-mouse
albumin antibody was produced in our laboratory and tested by
Western blot for specificity.
Kidney Carboxymethyllysine
Carboxymethyllysine (CML), a widely studied marker of advanced
glycation, was analyzed in kidneys with the method described by
Niquet-Léridon and Tessier (31) with the instrument parameters
detailed by Guilbaud et al. (16).
Carnosine and Anserine Determination
Carnosine and anserine were quantified based on the protocol of
Ref. 17. Deproteinized plasma (acute exercise study) and spot urine
(chronic exercise study) were diluted 1:20 and 1:25, respectively, in a
75% acetonitrile-25% water solution containing 10 M tyrosine-
histidine (mass-to-charge ratio: 319 Da) as an internal standard.
Samples were centrifuged at 13,000 g for 10 min to eliminate
excessive precipitate. The supernatant was used for further analysis.
Gastrocnemius muscle (acute study) and kidney tissue (chronic study)
were homogenized in extraction solution containing 10 mM HCl, 100
M phenanthroline (specific CN1 inhibitor), and tyrosine-histidine
internal standard (25 M for muscle tissue and 2 M for kidney
tissue) with a BeadBug D1030 tissue homogenizer. Homogenates
were sonicated on ice for 10 s and centrifuged at 13,000 g for 10 min.
The supernatant was diluted 1:1,500 (muscle homogenate) and 1:100
(kidney homogenate) in a 75% acetonitrile-25% water solution before
further analysis.
High-resolution ultraperformance liquid chromatography (UPLC;
Waters ACQUITY UPLC H-Class System) coupled with a Xevo
TQ-S micro triple quadrupole MS (LC-MS/MS) was used to identify
and quantify carnosine, anserine, and carnosine-aldehyde conjugate
Table 2. Chronic study: basic group characteristics
Number of Mice
(Male/Female) Body Weight, g Water Intake, mL/day Carnosinase-1 Activity, mol·mL1·h1
Week 4
WT 15 (7/8) 19.9  4.6 12.7  9.4 ND
ob/ob 19 (10/9) 28.8  5.0* 13.0  3.7 ND
ob/ob EX-T 19 (9/10) 27.2  2.9 15.1  4.3 ND
ob/ob hCN1 16 (7/9) 26.4  7.9 15.1  5.8 33.4  20.2
Week 24
WT 14 (7/7) 38.8  6.8 15.7  5.2 0.15  0.15
ob/ob 17 (9/8) 74.0  10.8* 29.4  15.3* 0.54  0.75
ob/ob EX-T 16 (7/9) 67.7  7.4 25.0  14.1 0.62  0.75
ob/ob hCN1 14 (6/8) 72.2  12.2 30.6  11.7 145.8  61.5†
Values are means  SD for the numbers of mice indicated. The following groups are shown: wild type (WT) mice, ob/ob mice, ob/ob mice with chronic
exercise training (EX-T), and ob/ob human carnosinase-1 transgenic (hCN1) mice. ND, not determined. *P  0.05, ob/ob vs. WT mice; †P 
 0.05 and 	 0.1
vs. ob/ob mice.
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levels. Carnosine, anserine, and carnosine-aldehyde conjugates were
separated with a Waters ACQUITY BEH HILIC column (1.7 m,
2.1  50 mm) equipped with an in-line frit filter unit. The elution of
analytes was achieved with a binary solvent system consisting of 10
mM ammonium formate and 0.125% formic acid in 5% acetonitrile-
95% water for mobile phase A and 10 mM ammonium formate and
0.125% formic acid in 95% acetonitrile-5% water for mobile phase B
at a flow rate of 0.55 mL/min. Initial conditions were 0.1:99.9 A:B
ramping to 99.9:0.1 A:B over 5 min before rapidly returning to
0.1:99.9 A:B over 0.5 min. This mobile phase composition was held
from 5.5 to 8 min to equilibrate the column for the next injection (5
L). Dipeptides were quantified with external standard curves, and
carnosine-aldehyde conjugates were quantified with the peak ratio of
histidyl-dipeptide to the tyrosine-histidine internal standard.
CN1 Activity
CN1 activity was quantified by fluorometric determination of
liberated histidine after carnosine addition [based on Teufel et al.
(48)]. Briefly, the reaction was initiated by the addition of 10 mM
carnosine (Flamma) to serum and stopped after a 10-min incubation at
37°C by the addition of 600 mM trichloroacetic acid (TCA). For
controls, TCA was added before carnosine. After centrifugation
(4,500 g, 15 min) supernatant was added to a mixture of o-phthalal-
dehyde (OPA; incomplete phthalaldehyde with 0.2% 2-mercaptoetha-
nol) and 4 M sodium hydroxide, and fluorescence was determined
after 40 min (excitation: 360 nm and emission: 465 nm).
Citrate Synthase Activity
Citrate synthase activity assay was based on the binding of coen-
zyme A (CoA-SH) to 5,5=-dithiobis(2-nitrobenzoic acid) (DTNB),
after initiation by oxaloacetic acid, and absorbance measured at 450
nm. In short, gastrocnemius muscle was homogenized in ice-cold
buffer consisting of 250 mM sucrose, 2 mM Na-EDTA, and 5 mM
Tris base (pH 7.4) and centrifuged for 10 min at 10,000 rpm. Protein
content was measured with a Total Protein Kit (Merck, Micro-Lowry,
Onishi & Barr Modification). Reagent solution (100 mM Tris base,
100 M DTNB, and 0.05 mM acetyl CoA, pH 8, 250 L) was added
to the samples (5 L, ~0.5 g/L protein) or standards (5 L CoA-SH),
after which the reaction was initiated by the addition of 5 L of 25
mM oxaloacetic acid. The linear part of the enzymatic reaction was
used to calculate, with a standard curve, the amount of CoA-SH that
was formed.
Statistical Analysis
All data are expressed as means  SD. For the acute study, one-
way ANOVA was performed to evaluate the effect of the interven-
tions on plasma and muscle carnosine and anserine. Significant results
were further evaluated by means of independent t tests. For the
chronic study, body weight and water intake were analyzed by means
of repeated measures with time (2) as within-subject and group (4) as
between-subjects factor. The evolution over time of serum CN1
activity of the hCN1 group was evaluated by means of a paired t test.
Repeated-measure parameters were evaluated with time as within
factor (3 or 4) and group (4) as between factor. In case of significant
interaction effects, the test was repeated per two groups and an
independent t test was performed per time point. Parameters measured
at week 24 were checked with one-way ANOVA with group (4) as
between factor and post hoc analysis when necessary. Correlations
were evaluated by means of Pearson correlations. Differences were
considered statistically significant at P 	 0.05.
RESULTS
Acute Study
Because CN1 hydrolyzes carnosine and anserine, we first
determined whether hCN1 overexpression in ob/ob mice en-
hanced CN1 activity and affected circulating and skeletal
muscle HCD levels. As expected, no CN1 activity was detected
in the serum of WT or ob/ob mice, whereas CN1 hydrolyzing
activity was significantly enhanced in ob/ob hCN1 mice
(6.04  0.94 mol·mL1·h1; Table 1). This CN1 activity was
higher compared with the CN1 activity of healthy subjects
(mean: ~1.5 mol·mL1·h1, unpublished data). Analysis of
the plasma by LC-MS/MS showed that HCD levels were
significantly decreased in ob/ob mice (0.28  0.16 M) com-
pared with WT mice (0.65  0.38 M, P 	 0.05). This
decrease can be attributed to both carnosine (WT: 0.36  0.32
M vs. ob/ob: 0.11  0.08 M) and anserine (WT: 0.29 
0.15 M vs. ob/ob: 0.16  0.08 M). As expected, overex-
pression of hCN1 in ob/ob mice resulted in a 
100-fold
decrease in circulating HCD (0.003  0.007 M, P 	 0.05)
compared with ob/ob mice. Acute running did not significantly
affect circulating carnosine and anserine levels in ob/ob mice
(P 
 0.1; Fig. 1A). Circulating carnosine-propanal levels
(carnosine bounded to the reactive carbonyl acrolein) were
significantly higher in ob/ob mice (7.73  2.10 nM) versus
WT mice (5.03  1.22 nM) and tended (0.05 
 P 	 0.1) to be
higher in exercising ob/ob mice (8.83  1.45 nM) compared
with resting (6.63  2.18 nM) obese control mice (data not
shown).
In these young animals, carnosine and anserine gastroc-
nemius levels were not dependent on obesity (Fig. 1B).
Furthermore, acute exercise or overexpression of hCN1 had
Fig. 1. Acute study: metabolism of histidine-containing dipeptides (HCD). A
and B: plasma (A) and gastrocnemius (B) carnosine and anserine content in
wild-type (WT) mice, ob/ob mice, ob/ob mice with acute exercise (EX), and
ob/ob human carnosinase-1 (hCN1) transgenic mice. LOD, limit of detection;
WW, wet weight. Values are means  SD. #P  0.05, ob/ob vs. WT mice;
*P  0.05 vs. ob/ob mice.
F1033CARNOSINASE-1 AND EXERCISE TRAINING IN DIABETIC NEPHROPATHY
AJP-Renal Physiol • doi:10.1152/ajprenal.00329.2019 • www.ajprenal.org
Downloaded from journals.physiology.org/journal/ajprenal at Univ Ziekenhuis (157.193.012.035) on June 19, 2020.
no effect on skeletal muscle HCD levels in these BTBR
ob/ob mice (Fig. 1B).
Chronic Study
To determine the effect of exercise training, ob/ob mice
were exercised at an aerobic intensity for 20 wk, running 5
days/wk for 1 h at 10 m/min. The body weight gain after 20
wk was more than twofold higher in ob/ob versus WT mice.
Exercise training or hCN1 overexpression did not influence
the evolution of body weight over time (Table 2). Serum
carnosinase activity (week 24) was markedly higher in
hCN1 transgenic mice (145.8  61.5 mol·mL1·h1) ver-
sus nontransgenic mice (0.54  0.75 mol·mL1·h1) and
increased approximately fourfold from 4 to 24 wk in trans-
genic mice (Table 2).
Development of diabetes in BTBR ob/ob mice. To determine
the effect of exercise training and CN1 overexpression on the
development of diabetes, we measured fasting serum glucose
levels. The results showed that serum glucose levels were three- to
fourfold higher in ob/ob mice at weeks 14 and 24 compared with
WT mice (week 14: 674.02  297.54 vs. 170.76  40.49 mg/dL
and week 24: 724.90  502.58 vs. 265.67  66.75 mg/dL; Fig.
2A) but were not affected by exercise training or hCN1 overex-
pression.
Plasma fructosamine content, a long-term biomarker of
glucose overload, was significantly higher at weeks 14 (57%)
and 24 (48%) in ob/ob versus WT mice. Fructosamine levels
returned to baseline levels from week 14 to week 24 in ob/ob
mice (P 	 0.05; Fig. 2B). The increase in fructosamine levels
was independent of exercise training or hCN1 overexpression
(Fig. 2B). Total serum protein levels were higher in ob/ob mice
(71.58  21.92 g/L) compared with WT mice at week 24
(61.90  8.48 g/L; data not shown). Therefore, it is suggested
that reduced circulating protein levels were not the cause of the
decline in serum fructosamine levels between weeks 14 and 24.
In contrast to the glucose-based markers, serum triglycerides
and cholesterol levels were significantly affected by hCN1
overexpression. Serum triglycerides evolved differentially over
time in ob/ob versus ob/ob hCN1 mice, with a trend to
significant higher values at week 14 (57%) but not at week 24
(Fig. 2C). Similar to triglycerides, cholesterol levels were
significantly increased (109%) at 14 wk of age in ob/ob
hCN1 mice compared with ob/ob mice but not at 24 wk. No
effect of exercise training on the evolution over time of serum
triglycerides and cholesterol was observed (Fig. 2, C and D).
The effect of the interventions (hCN1 and exercise training)
on the different diabetes-related parameters were not depen-
dent on sex (data not shown) except for the development of
hyperglycemia. The development of hyperglycemia was more
pronounced in male (week 24: 1,001.41  309.48 mg/dL)
versus female (week 24: 462.55  253.30 mg/dL, P 	 0.05)
obese mice. Furthermore, male ob/ob EX-T and ob/ob hCN1
mice had significantly lower serum glucose levels (20% and
18%, respectively) compared with male ob/ob mice at week
14, whereas no differences were found between different obese
groups in female mice (data not shown).
Development of DN in BTBR ob/ob mice. The development
of DN was evaluated by measuring the urinary albumin-to-
Fig. 2. Development of diabetes in BTBR ob/ob mice. AD: fasted serum glucose (A), fructosamine (B), triglycerides (C), and cholesterol (D) were quantified
at 4, 14, and 24 wk of age in wild-type (WT) mice, ob/ob mice, ob/ob mice with exercise training (EX-T), and ob/ob human carnosinase-1 (hCN1) transgenic
mice. Values are means  SD. #P  0.05, ob/ob vs. WT mice; *P  0.05 vs. ob/ob mice; $P 
 0.05 and 	 0.1 vs. ob/ob mice at the same time point.
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creatinine ratio. At the end of the intervention, the albumin-
to-creatinine ratio of ob/ob mice was 1,194.62  963.86
g/mg, i.e., ~25-fold higher in ob/ob versus WT mice
(47.86  21.87 g/mg), which corresponds with a stage of
advanced DN. The albumin-to-creatinine ratio was not af-
fected by the exercise intervention, but ob/ob hCN1 mice
(2,182.24  1,667.66 g/mg) had significantly higher levels
(82%) compared with ob/ob mice (Fig. 3B).
Renal lesions were evaluated by scoring the degree of
mesangial matrix expansion. This expansion was 3.8-fold more
pronounced in ob/ob versus WT mice and was further aggra-
vated by hCN1 overexpression (22%, P 	 0.05; Fig. 3C).
Representative images of a WT, an ob/ob, and a ob/ob hCN1
mouse are shown in Fig. 3A. The number of podocytes was not
affected by obesity or by hCN1 overexpression (P 
 0.1; Fig.
3D). Also, weak to mild interstitial fibrosis was seen both in the
ob/ob mouse and ob/ob hCN1 mouse.
Glomerular hypertrophy was evaluated by measuring the
surface areas (m2) of the glomerular tuft, Bowman’s space,
and whole glomerulus (Fig. 3, E–G). The three different
areas were expanded in ob/ob versus WT mice (P 	 0.05),
and overexpression of hCN1 further aggravated the hyper-
trophy in the glomerular tuft (P 	 0.05; Fig. 3E) and whole
glomerulus (P 	 0.05; Fig. 3G) but not in Bowman’s space
(P 
 0.1; Fig. 3F).
None of the above-mentioned DN-related parameters was af-
fected by the chronic aerobic exercise training protocol (Fig. 3).
Metabolism of HCD and acrolein adducts. To further elu-
cidate the effect of hCN1 overexpression, HCD levels were
quantified in the kidney, skeletal muscle, and urine in 24-wk-
old mice. Carnosine and anserine were remarkably lower in
both the kidney (Fig. 4A) and muscle (Fig. 4B) in ob/ob versus
WT mice (P 	 0.05). Kidney (95%, P 	 0.05) and muscle
(20%, P 	 0.1) anserine were further declined in hCN1
transgenic ob/ob versus nontransgenic ob/ob mice (Fig. 4, A
and B).
The evolution of urinary excretion of HCD was not
dependent on obesity or the different interventions (P 
 0.1;
Fig. 4C). Urinary carnosine-propanal adducts were not de-
tectable throughout the intervention period. In contrast,
urinary carnosine-propanol levels were above the limit of
detection and similar between WT and ob/ob mice at 4 and
24 wk of age and slightly higher at 14 wk of age in ob/ob
versus WT mice. In ob/ob hCN1 mice, urinary carnosine-
propanol levels were not different at 4 and 14 wk from ob/ob
mice but, however, were 20-fold lower in ob/ob hCN1 at 24
wk of age (P 	 0.05; Fig. 4D).
Kidney carnosine-propanol levels were not detectable in any
of the groups. In contrast, kidney carnosine-propanal levels
were detectable (overall mean  SD: 3.09  0.79 pmol/mg
Fig. 3. Development of diabetic nephropathy in BTBR ob/ob mice. A: representative images of glomeruli (periodic acid-Schiff-stained sections) of (from left to
right) wild-type (WT) mice, ob/ob mice, and ob/ob human carnosinase-1 (hCN1) transgenic mice. B–G: urinary albumin-to-creatinine ratio (B), degree of
mesangial matrix expansion (C), number of podocytes (D), and surface area of the glomerular tuft (E), Bowman’s space (F), and whole glomerular area (G) at
week 24 for WT mice, ob/ob mice, ob/ob mice with exercise training (EX-T), and ob/ob hCN1 mice. AU, arbitrary units; WT1, Wilms’ tumor-1 protein. Values
are means  SD. #P  0.05, ob/ob vs. WT mice; *P  0.05 vs. ob/ob mice.
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wet wt) but not affected by obesity, hCN1 overexpression, or
the chronic exercise intervention (data not shown).
Correlations. The amount of HCD in the muscle (r  0.38
and r  0.38, P 	 0.05) and especially in the kidney
(r  0.76 and r  0.69, P 	 0.05) was negatively corre-
lated to mesangial matrix expansion (Fig. 5A) and glomerular
hypertrophy (Fig. 5B), respectively.
Carboxymethyllysine. The amount of protein-bound kidney
CML was quantified as a marker of glycation damage in this
mouse model. At the age of 24 wk, kidney CML levels (overall:
203.77  39.33 mol/mol lysine) were independent of obesity,
exercise training, and hCN1 overexpression (data not shown).
Citrate synthase activity. The activity of the citrate synthase
enzyme was measured in gastrocnemius muscles to elucidate
the effect of chronic exercise training on the aerobic capacity
of BTBR ob/ob mice. After 20 wk of aerobic exercise training,
citrate synthase activity was approximately twofold higher in
ob/ob EX-T mice (132.9  61.1 mol·min1·g protein1)
Fig. 4. Metabolism of histidine-containing dipeptides (HCD) in BTBR ob/ob mice. A–C: kidney (A; week 24), gastrocnemius (B; week 24), and urinary (C; weeks
4, 14, and 24) HCD content in wild-type (WT) mice, ob/ob mice, ob/ob mice with exercise training (EX-T), and ob/ob human carnosinase-1 (hCN1) transgenic
mice. Values are means  SD. #P  0.05, ob/ob vs. WT mice; *P  0.05 vs. ob/ob mice; $P 
 0.05 and 	 0.1 vs. ob/ob mice. D: urinary carnosine-propanol
adducts (weeks 4, 14, and 24) in WT, ob/ob, ob/ob EX-T, and ob/ob hCN1 mice. WW, wet weight. Values are means  SD. *P  0.05 vs. ob/ob mice at the
same time point.
Fig. 5. Correlations. A and B: correlations between kidney histidine-containing dipeptide (HCD) content and mesangial matrix expansion (A) and whole glomerular area
(B) in wild-type (WT) mice, ob/ob mice, ob/ob mice with exercise training (EX-T), and ob/ob human carnosinase-1 (hCN1) transgenic mice. WW, wet weight.
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compared with control ob/ob mice (66.6  50.0 mol·min1·g
protein1; P 	 0.05) and not affected by obesity (WT:
45.2  46.6 mol·min1·g protein1; P 
 0.1) or hCN1 over-




The main finding of the present study is that changes in renal
HCD availability are accompanied with variations in the de-
velopment of DN in BTBR ob/ob mice. Kidney HCD content
is already compromised in the diabetic state, and DN is
significantly accelerated and aggravated when it is further
reduced by hCN1 overexpression. The underlying mechanism
seems lipid rather than sugar related, since biochemical mark-
ers indicate that this does not coincide with hyperglycemic
state (Fig. 2, A and B) or glycation damage but rather with an
attenuation of hyperlipidemic state and a diminished capacity
to quench, eliminate, and protect against lipid-derived reactive
carbonyl species, such as acrolein. Interestingly, overexpres-
sion of hCN1 had opposite effects on the development of DN
(albumin-to-creatinine ratio and glomerular hypertrophy) as
carnosine supplementation, which has been investigated in the
same mouse model by Albrecht et al. (1). The second hypoth-
esis, i.e., that exercise training attenuates the development of
DN through the release of HCD from muscular depots, was not
supported by our findings. There was no substantial elevation
of circulating HCD during acute exercise in this animal model,
and there was no protective effect of exercise training on DN.
The results of the present study suggest that the amount of
body burden of HCD determines the potential for scavenging
reactive carbonyl species such as acrolein and thereby plays a
(key) role in the development of DN. Diabetes in itself resulted
in strongly reduced gastrocnemius (48% and 28%, respec-
tively; Fig. 4B), kidney (58% and 47%, respectively; Fig.
4A), and plasma (69% and 44%, respectively; Fig. 1A)
carnosine and anserine levels. This is in accordance with
reduced HCD levels in the kidney [from 90% to 98% (34,
35, 38)], retina [31% (36)], liver [78% (28)], and brain
[64% (5)] in different type 1 and type 2 diabetic models but
not with increased levels in skeletal muscle of patients with
type 2 diabetes [39% (46)]. Different reports have suggested
that carnosine can act as a sacrificial dipeptide by binding and
eliminating deleterious agents such as reactive carbonyl spe-
cies. A disproportional accumulation of reactive carbonyl spe-
cies, which takes place, for example, during diabetes, can
therefore result in a shortage of tissue carnosine or anserine.
Compared with the reducing effect of diabetes on carnosine
and anserine levels, hCN1 overexpression resulted not only in
lower circulating HCD levels (carnosine: 97% and anserine:
more than 99%) but in strongly reduced whole body carnos-
ine and anserine stores. Diminished levels of carnosine and
anserine were observed in kidney (week 24: 53% and 95%,
respectively) and gastrocnemius tissue (week 24: anserine:
20%) in hCN1 transgenic versus nontransgenic ob/ob mice
(Fig. 4, A and B).
Importantly, there was a positive correlation between the
amount of carnosine (r  0.64, P 	 0.05) and anserine
(r  0.33, P 	 0.05) in the kidney and urinary carnosine-
acrolein adducts. Kidney HCD were further also negatively
correlated with different markers of DN (Fig. 5). Unfortu-
nately, it is not known whether kidney HCD levels were
enhanced after carnosine supplementation in BTBR ob/ob mice
in the study of Albrecht et al. (1) and could therefore be the
main underlying mechanism for an attenuated development of
DN in carnosine-supplemented mice. However, as 1) different
rodent studies have shown that kidney HCD are enhanced upon
oral supplementation of carnosine (34), -alanine (unpublished
data), D-carnosine (2), and carnosinol (3) and as 2) the PEPT2
transporter is highly abundant in renal cells (22, 26), it is highly
likely that kidney HCD levels were enhanced in carnosine-
supplemented BTBR ob/ob mice. Enhancing the dietary intake
of HCD, which potentially maintains kidney carnosine and
anserine during periods of increased exposure of reactive
carbonyl species, should therefore be further explored as a
promising therapeutic strategy to offset DN. Unfortunately, our
study is limited by the lack of a direct comparison between the
effect of hCN1 overexpression and carnosine supplementation
on both kidney HCD levels and DN.
The observed effect of hCN1 overexpression on DN in mice
confirms the genetic link between polymorphisms of the
CNDP1 gene, the gene encoding the CN1 enzyme, and the
prevalence of DN in patients with diabetes (21). The dramatic
decline in kidney carnosine and anserine levels in hCN1
transgenic mice together with the strong correlation between
kidney HCD levels and the degree of DN (Fig. 5) brings us to
the hypothesis that the underlying protective mechanism of low
CN1 activity (21) could not only be higher circulating carnos-
ine levels but also higher renal carnosine and anserine levels.
Indeed, in this study, serum CN1 activity was negatively
correlated with renal carnosine (r  0.33, P 	 0.05) and
especially anserine (r  0.70, P 	 0.05) levels. These results
can therefore be a start to further elucidating the exact role of
renal HCD in (diabetic) kidney diseases. The development of a
mouse model with podocyte-specific CN1 overexpression,
which would probably only result in decline in the kidney and
not full body HCD levels, would be able to further unravel the
contribution of renal HCD to the development of DN. Future
research will have to elucidate whether serum CN1 activity and
the risk for developing DN are also related to renal HCD levels
in humans.
The present study is the first to document that overexpres-
sion of the hCN1 enzyme results in a faster development of
hyperlipidemia in diabetic mice (as reflected by higher fasting
triglycerides and cholesterol at week 14; Fig. 2, C and D).
These results are in line with an improved lipidemic profile in
different diabetes or metabolic syndrome rodent models after
long-term carnosine supplementation (2, 4, 8, 25). The levels
of serum triglycerides were furthermore also significantly re-
duced in patients with type 2 diabetes who received oral
supplements of 1 g carnosine/day for 12 wk (18). Although
evidence is accumulating for an antihyperlipidemic effect of
carnosine, no underlying mechanism has been reported so far.
Novel approaches, such as lipidomics and proteomics, are
needed to further explain this lipid regulation mechanism.
Anyhow, it is likely that the favorable effects of carnosine (and
adverse effects of CN1) on dyslipidemia and hypercholester-
emia will contribute to a lower risk of developing diabetes-
induced microvascular and macrovascular complications.
Different therapeutic approaches are currently being devel-
oped to encounter the negative effects of CN1 upon carnosine
supplementation. The administration of carnosinol, a chemi-
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cally synthetized carnosine analog that is well absorbed in the
intestinal wall but not degraded by CN1, strongly and dose
dependently counteracted several consequences of metabolic
syndrome [inflammation, dyslipidemia, insulin resistance, and
steatohepatitis (3)]. Anserine, a naturally occurring carnosine
analog that is also less vulnerable to degradation by CN1 (9),
efficiently reduces fasting plasma glucose levels, proteinuria,
and vascular permeability in db/db mice (33). In parallel to the
development of carnosinase-resistant carnosine analogs, CN1
blockers are also currently under investigation (37).
Surprisingly, 20 wk of chronic aerobic exercise training did
not retard the progression of diabetes or DN in the BTBR ob/ob
mouse model. This is in contrast with previous reports on
treadmill-trained db/db mice (14, 45) and different high-fat (7,
40), heminephrectomized (49), and streptozotocin-induced
(23) diabetic rat models. All studies reported a slower devel-
opment of early DN (mostly based on the albumin-to-creati-
nine ratio and mesangial matrix expansion) after 5–12 wk of
aerobic treadmill running. The lack of an exercise-induced
amelioration of the development of DN is especially surprising
as the chronic exercise training program enhanced citrate
synthase enzyme activity, a marker of mitochondrial content
(24). Our intervention doubled citrate synthase activity,
whereas others have reported increases of ~30–50% following
chronic exercise intervention in obese mice models (14, 15,
20). It can be concluded that a doubling in citrate synthase
enzyme activity did not ameliorate the disturbance in glucose
and lipid metabolism, or the development of DN, in our BTBR
ob/ob model. A possible reason for the absence of a protec-
tive effect of chronic exercise in our study (Fig. 2, A and B)
could be the very high glucose levels, possibly leading to
severe ketoacidosis, lower exercise tolerance, or dehydra-
tion during exercise training. This is in accordance with the
absence of an antihyperglycemic effect of exercise in db/db
mice with very high circulating glucose levels (14, 27)
compared with db/db mice with lower glucose levels (45)
and in accordance with absence of an exercise-induced
improvement in glycemic control in subjects with high (
13
mmol/L) fasting glucose levels (44).
In contrast to previous reports (11, 30), circulating carnosine
and anserine were not significantly enhanced after an acute
bout of exercise in mice lacking the serum CN1 enzyme. The
degree of release could be dependent on different exercise mo-
dalities, such as intensity and duration, but can also be dependent
on other factors, such as perceived stress (treadmill vs. running
wheel) or mouse strain. The lack of exercise-induced release of
carnosine and anserine may also partially explain the absence
of a protective effect of the chronic exercise program on
diabetes and DN.
In conclusion, we have shown, for the first time, that
overexpression of the hCN1 enzyme in BTBR ob/ob mice
aggravates the development of advanced glomerular lesions.
However, a chronic aerobic exercise training program did
not affect diabetes or DN. Our data further suggest that the
amount of renal HCD is closely linked to the severity of DN.
Developing a supplementation regimen that efficiently en-
hances renal carnosine and anserine levels in humans should
be explored as potential therapeutic target to reduce the risk
of developing DN.
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